Mika Caplan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mika Caplan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Carolyne Bardeleben
Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, California, USA
1 shared publicationCatalina Amador
Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, USA
1 shared publication- Irina Kufareva
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA
1 shared publication - JoAnn Trejo
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
1 shared publication - Kanika Dhawan
Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA
1 shared publication Karli J. Wittorf
Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, USA
1 shared publication
Latest Publications
- Open Access
- 21 May 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (7) , 110270
ARRDC3 tyrosine phosphorylation functions as a switch to control c-Src versus WWP2 interactions and distinct scaffolding functions
- 21 May 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (7) , 110270
Open AccessARRDC3 tyrosine phosphorylation functions as a switch to control c-Src versus WWP2 interactions and distinct scaffolding functions
- Open Access
- 17 February 2022
- Published by Springer Nature in Leukemia
- Vol. 36 (5) , 1296-1305
Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML
Acute myeloid leukemia (AML) is a devastating cancer affecting the hematopoietic system. Previous research has relied on RNA sequencing and microarray techniques to study the downstream effects of genomic alterations. While these studies have proven efficacious, they fail to capture the changes that occur at the proteomic level. To interrogate the effect of protein expression alterations in AML, we performed a quantitative mass spectrometry in parallel with RNAseq analysis using AML mouse models. These combined results identified 34 proteins whose expression was upregulated in AML tumors, but strikingly, were unaltered at the transcriptional level. Here we focus on mitochondrial electron transfer proteins ETFA and ETFB. Silencing of ETFA and ETFB led to increased mitochondrial activity, mitochondrial stress, and apoptosis in AML cells, but had little to no effect on normal human CD34+ cells. These studies identify a set of proteins that have not previously been associated with leukemia and may ultimately serve as potential targets for therapeutic manipulation to hinder AML progression and help contribute to our understanding of the disease.
- 17 February 2022
- Published by Springer Nature in Leukemia
- Vol. 36 (5) , 1296-1305
Open AccessMulti-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML
Acute myeloid leukemia (AML) is a devastating cancer affecting the hematopoietic system. Previous research has relied on RNA sequencing and microarray techniques to study the downstream effects of genomic alterations. While these studies have proven efficacious, they fail to capture the changes that occur at the proteomic level. To interrogate the effect of protein expression alterations in AML, we performed a quantitative mass spectrometry in parallel with RNAseq analysis using AML mouse models. These combined results identified 34 proteins whose expression was upregulated in AML tumors, but strikingly, were unaltered at the transcriptional level. Here we focus on mitochondrial electron transfer proteins ETFA and ETFB. Silencing of ETFA and ETFB led to increased mitochondrial activity, mitochondrial stress, and apoptosis in AML cells, but had little to no effect on normal human CD34+ cells. These studies identify a set of proteins that have not previously been associated with leukemia and may ultimately serve as potential targets for therapeutic manipulation to hinder AML progression and help contribute to our understanding of the disease.